Improvement in soluble expression levels of a diabody by exchanging expression vectors

Protein Expression and Purification

Volumn 62, Issue 1, 2008, Pages 15-20

  Liu, Fang ^a   Chen, Zhong ^a   Jiang, Wenguo ^b   Yang, Chunzheng ^a   Xiong, Dongsheng ^a   Zhu, Zhenping ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

B cell lymphoma; Bispecific antibody; Diabody; Soluble expression and purification

Indexed keywords

BISPECIFIC ANTIBODY; CD20 ANTIGEN; CD3 ANTIGEN;

ANTIBODY COMBINING SITE; ARTICLE; B CELL LYMPHOMA; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LEUKEMIA CELL LINE; METABOLISM; SOLUBILITY; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD20; ANTIGENS, CD3; BINDING SITES, ANTIBODY; CELL LINE, TUMOR; ESCHERICHIA COLI; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC VECTORS; HUMANS; JURKAT CELLS; LYMPHOMA, B-CELL; SOLUBILITY;

ESCHERICHIA COLI;

EID: 53149129402     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.07.002     Document Type: Article

References (39)

1. Kufer P., Lutterbuse R., and Baeuerle P.A. A revival of bispecific antibodies. Trends Biotechnol. 22 (2004) 238-244
2. Cao Y., and Lam L. Bispecific antibody conjugates in therapeutics. Adv. Drug Deliv. Rev. 55 (2003) 171-197
3. Kontermann R.E. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol. Sin. 26 (2005) 1-9
4. Shahied L.S., Tang Y., Alpaugh R.K., Somer R., Greenspon D., and Weiner L.M. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format. J. Biol. Chem. 279 (2004) 53907-53914
5. Holliger P., Prospero T., and Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448
6. Adams G.P., Schier R., McCall A.M., Crawford R.S., Wolf E.J., Weiner L.M., and Marks J.D. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer 77 (1998) 1405-1412
7. Kriangkum J., Xu B., Nagata L.P., Fulton R.E., and Suresh M.R. Bispecific and bifunctional single chain recombinant antibodies. Biomol. Eng. 18 (2001) 31-40
8. Wu A.M., Chen W., Raubitschek A., Williams L.E., Neumaier M., Fischer R., Hu S.Z., Odom-Maryon T., Wong J.Y., and Shively J.E. Immunotechnology 2 (1996) 21-36
9. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1 (2001) 118-129
10. von Mehren M., Adams G.P., and Weiner L.M. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54 (2003) 343-369
11. Kipriyanov S.M., and Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr. Opin. Drug Discov. Devel. 7 (2004) 233-242
12. Gao Y., Xiong D., Yang M., Liu H., Peng H., Shao X., Xu Y., Xu C., Fan D., Qin L., Yang C., and Zhu Z. Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein × anti-CD3 diabody. Leukemia 18 (2004) 513-520
13. Schlereth B., Fichtner I., Lorenczewski G., Kleindienst P., Brischwein K., da Silva A., Kufer P., Lutterbuese R., Junghahn I., Kasimir-Bauer S., Wimberger P., Kimmig R., and Baeuerle P.A. Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res. 65 (2005) 2882-2889
14. Asano R., Sone Y., Makabe K., Tsumoto K., Hayashi H., Katayose Y., Unno M., Kudo T., and Kumagai I. Humanization of the bispecific epidermal growth factor receptor CD3 diabody and its efficacy as a potential clinical reagent. Clin. Cancer Res. 12 (2006) 4036-4042
15. Bühler P., Wolf P., Gierschner D., Schaber I., Katzenwadel A., Schultze-Seemann W., Wetterauer U., Tacke M., Swamy M., Schamel W.W.A., and Elsässer-Beile U. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. Immunother. 57 (2008) 43-52
16. Kipriyanov S.M., Moldenhauer G., Strauss G., and Little M. Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells. Int. J. Cancer 77 (1998) 763-772
17. Kipriyanov S.M., Cochlovius B., Schafer H.J., Moldenhauer G., Bahre A., Le Gall F., Knackmuss S., and Little M. Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J. Immunol. 169 (2002) 137-144
18. de Gast G.C., Haagen I.A., van Houten A.A., Klein S.C., Duits A.J., deWeger R.A., Vroom T.M., Clark M.R., Phillips J., and van Dijk A.J. CD8 T cell activation after intravenous administration of CD3 × CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol. Immunother. 40 (1995) 390-396
19. Haagen I.A., Geerars A.J., de Lau W.B., Bast B.J., and de Gast B.C. The efficacy of CD3 × CD19 bispecific monoclonal antibody (BsAb) in a clonogenic assay: the effect of repeated addition of BsAb and interleukin-2. Blood 85 (1995) 3208-3212
20. Kipriyanov S.M., Moldenhauer G., Schuhmacher J., Cochlovius B., Von der Lieth C.W., Matys E.R., and Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 293 (1999) 41-56
21. Bohlen H., Manzke O., Titzer S., Lorenzen J., Kube D., Engert A., Abken H., Wolf J., Diehl V., and Tesch H. Prevention of Epstein-Barr virus-induced human B-cell lymphoma in severe combined immunodeficient mice treated with CD3 × CD19 bispecific antibodies, CD28 monospecific antibodies and autologous T cells. Cancer Res. 57 (1997) 1704-1709
22. Manzke O., Titzer S., Tesch H., Diehl V., and Bohlen H. CD3 × CD19 bispecific antibodies and CD28 costimulation for locoregional treatment of low malignancy non-Hodgkin's lymphoma. Cancer Immunol. Immunother. 45 (1997) 198-202
23. Daniel P.T., Kroidl A., Kopp J., Sturm I., Moldenhauer G., Dorken B., and Pezzutto A. Immunotherapy of B-cell lymphoma with CD3 × 19 bispecific antibodies: costimulation via CD28 prevents "veto" apoptosis of antibody targeted cytotoxic T cells. Blood 92 (1998) 4750-4757
24. Löffler A., Kufer P., Lutterbuse R., Zettl F., Daniel P.T., Schwenkenbecher J.M., Riethmu{combining double acute accent}ller G., Dörken B., and Bargou R.C. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95 (2000) 2098-2103
25. Cochlovius B., Kipriyanov S.M., Stassar M.J.J.G., Schuhmacher J., Benner A., Moldenhauer G., and Little M. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T Cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res. 60 (2000) 4336-4341
26. Cochlovius B., Kipriyanov S.M., Stassar M.J.J.G., Christ O., Schuhmacher J., Strauss G., Moldenhauer G., and Little M. Treatment of human B cell lymphoma xenografts with a CD3 × CD19 diabody and T cells. J. Immunol. 165 (2000) 888-895
27. Stel A.J., Kroesen B., Jacobs S., Groen H., de Leij L.F.M.H., Kluin-Nelemans H.C., and Withoff S. The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20 × 3. J. Immunol. 173 (2004) 6009-6016
28. Uckun F.M., Jaszcz W., Ambrus J.L., Fauci A.S., Gajl-Peczalska K., Song C.W., Wick M.R., Myers D.E., Waddick K., and Ledbetter J.A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 71 (1988) 13-29
29. Pulczynski S., Boesen A.M., and Jensen O.M. Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study. Blood 81 (1993) 1549-1557
30. Ma D., McDevitt M.R., Barendswaard E., Lai L., Curcio M.J., Pellegrini V., Brechbiel M.W., and Scheinberg D.A. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 16 (2002) 60-66
31. Xiong D.S., Xu Y.F., Liu H.Z., Peng H., Shao X.F., Lai Z.Z., Fan D.M., Yang M., Han J.L., Xie Y., Yang C.Z., and Zhu Z.P. Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 × anti-CD3 bispecific diabody. Cancer Lett. 177 (2002) 29-39
32. Liu Y., Zhao T.J., Yan Y.B., and Zhou H.M. Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system. Protein Expr. Purif. 44 (2005) 155-161
33. Bothmann H., and Pluckthun A. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat. Biotechnol. 16 (1998) 376-380
34. Le Gall F., Reusch U., Little M., and Kipriyanov S.M. Effect of linker sequences between the antibody variable domains on the formation stability and biological activity of a bispecific tandem diabody. Protein Eng. Des. Sel. 17 (2004) 357-366
35. Takemura S., Asano R., Tsumoto K., Ebara S., Sakurai N., Katayose Y., Kodama H., Yoshida H., Suzuki M., Imai K., Matsuno S., Kudo T., and Kumagai I. Construction of a diabody (small recombinant bispecific antibody) using a refolding system. Protein Eng. 13 (2000) 583-588
36. Asano R., Kudo T., Nishimura Y., Makabe K., Hayashi H., Suzuki M., Tsumoto K., and Kumagai I. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment. J. Biochem. (Tokyo) 132 (2002) 903-909
37. Holliger P., and Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23 (2005) 1126-1136
38. Peipp M., and Valerius T. Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. 30 (2002) 507-511
39. Balan A., de Souza C.S., Moutran A., Café Ferreira R.C., Franco C.S., Ramos C.H.I., and de Souza Ferreira L.C. Purification and in vitro characterization of the maltose-binding protein of the plant pathogen Xanthomonas citri. Protein Expr. Purif. 43 (2005) 103-110